Related Experiment Video
Updated: Jun 17, 2025

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Coformulated Bictegravir/Emtricitabine/Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Assault: A
Cabrera-López Teresita de Jesús1, Pérez-Barragán Edgar2, Nava-Campos Carlos Ruben1
1Department of Gynecology and Care for Victims of Sexual Assault, Clínica Especializada Condesa Iztapalapa, Mexico City, Mexico.
Abstract:
We report the experience of bictegravir/emtricitabine/tenofovir alafenamide for nonoccupational postexposure prophylaxis in sexual assault cases. Between June 2021 and October 2023, 39 individuals completed the 28-day follow-up; 41% experienced some side effects, and 1 person discontinued the drug because of a rash. No individuals seroconverted to HIV during the follow-up period.
More Related Videos
Related Concept Videos
Sexually Transmitted Infections
Retrovirus Life Cycles

